This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

Cesar A. Lopez, MD; Balavenkatesh Kanna, MD, MPH

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We would like to raise the following issues regarding the interesting article by Hollander et al.¹ The high dropout rates (176 of the 630 randomized subjects) reported in the study may have reduced power and comparability and thus limit the validity of the results.² Furthermore, including sample size estimation in the manuscript would facilitate assessment of the impact of follow-up losses on the study results.

The investigators must describe cardiovascular adverse events in detail, in view of recent reports showing that rosiglitazone is associated with higher risk of myocardial infarction.³ In addition, confounder analysis should be performed to evaluate if the increase in cardiovascular events reported in the study could be attributed to the high prevalence of risk factors in the subjects as reported by the authors.

Although diet and exercise are significant confounders of diabetes control,^4-5 these variables were neither measured . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?